KPRX Stock Forecast: Kiora Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 60 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kiora Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (14): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KPRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Aug 2023 | Maxim Group | Maintains | Buy | — |
| 12 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Feb 2023 | Maxim Group | Upgrade | Buy | — |
| 8 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Feb 2023 | Ladenburg Thalmann | Reiterates | Buy | — |
| 25 Aug 2022 | Ladenburg Thalmann | Initiates | Buy | $6.50 |
| 15 Aug 2022 | Maxim Group | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
KPRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KPRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kiora Pharmaceuticals, Inc. returned −60.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KPRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.2×
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 34% of US stocks
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −67.7%
- Return on assets
- −21.3%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kiora Pharmaceuticals, Inc. has a market value of $3.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$11.0M.
Free cash flow in the twelve months to 30 June 2026: −$8.6M.
Kiora Pharmaceuticals, Inc. employs 13 people.
Data provided by Twelve Data
KPRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KPRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kiora Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KPRX
How does Ticker Nerd's model rank KPRX?
As at 21 Nov 2026, Kiora Pharmaceuticals, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
What is the KPRX stock forecast for 2030?
No analyst covering Kiora Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
How has KPRX stock performed over the past year?
Kiora Pharmaceuticals, Inc. returned -60.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kiora Pharmaceuticals, Inc. do?
Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function.
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function. Its pipeline includes therapies under development for inherited retinal disorders, inflammatory eye conditions, and corneal repair applications, reflecting a specialization in diseases with limited treatment options. Kiora Pharmaceuticals Inc. works at the intersection of eye health and drug development, addressing both rare and more broadly relevant ophthalmic indications through its research and clinical programs. Headquartered in Encinitas, California, the company plays a niche role in the healthcare sector by advancing experimental therapies aimed at unmet needs in vision care.
CEO Dr. Brian M. Strem Ph.D. · 13 employees · United States · https://www.kiorapharma.com